Risiko Miokarditis dan Perikarditis Pasca Vaksinasi COVID-19 mRNA

Oleh :

dr. Inge Nandya H

Miokarditis dan perikarditis telah dilaporkan sebagai salah satu efek samping pasca vaksinasi COVID-19 jenis mRNA, baik Pfizer-BioNTech maupun Moderna. Terdapat laporan adanya peningkatan kasus miokarditis dan perikarditis pada usia muda setelah vaksinasi COVID-19 di Amerika Serikat sejak April 2021. Sedangkan European Medicines Agency’s (EMA) safety committee, yaitu The Pharmacovigilance Risk Assessment Committee (PRAC), menyebutkan bahwa miokarditis dan perikarditis adalah kejadian yang sangat jarang setelah vaksin mRNA COVID-19.[1,2]

Vaksin COVID-19 mRNA

Vaksin COVID-19 mRNA yang tersedia dan digunakan di Indonesia yaitu vaksin mRNA-1273 (vaksin Moderna atau SpikeVax) dan vaksin BNT162b2-mRNA (vaksin Pfizer atau Corminaty). Kedua vaksin ini bekerja dengan cara memberikan respon imun terhadap antigen spike (S) pada severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).[3-6]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis: European Medicines Agency; 2021. https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis.
2. Centers for Disease Control and Prevention. Myocarditis and pericarditis considerations: Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html.
3. Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yunihastuti E, et al. COVID-19 vaccines: current status and implication for use in Indonesia. Acta Med Indones. 2020;52(4):388-412.
4. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/341785.
5. World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: World Health Organization; 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1.
6. Kementerian Kesehatan Republik Indonesia. Vaksinasi booster bagi tenaga kesehatan untuk memaksimalkan perlindungan pelayanan kesehatan: Kementerian Kesehatan Republik Indonesia; 2021. https://ktki.kemkes.go.id/info/node/317.
7. Dominguez F, Kuhl U, Pieske B, Garcia-Pavia P, Tschöpe C. Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol. 2016;69:178–87.
8. Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. Vaccine. 2021;39(5):839–45. doi: 10.1016/j.vaccine.2020.12.046.
9. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 2021. doi:10.1001/jama.2021.1344.
10. Montgomery J, Ryan M, Engler R, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021; doi:10.1001/jamacardio.2021.2833.
11. Kim HW, Jenista ER, Wendell DC, .Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021. doi:10.1001/jamacardio.2021.2828.
12. Hudson B, Mantooth R, DeLaney M. Myocarditis and pericarditis after vaccination for COVID-19. JACEP Open. 2021;2:e12498. doi: https://doi.org/10.1002/emp2.12498.
13. Government of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Recommendations on the use of COVID-19 Vaccines. Public Health Agency of Canada; 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html.
14. Shimabukuro T. COVID-19 Vaccine safety updates, Advisory Committee on Immunization Practices (ACIP): Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf.
15. Government of Israel. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021. Jerusalem: Government of Israel; 2021. https://www.gov.il/en/departments/news/01062021-03.
16. Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18:169–93. doi: 10.1038/s41569-020-00435-x.
17. Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/05-COVID-Wallace-508.pdf.
18. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on immunization practices – United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7027e2.
19. Bozkurt B, Kamat I, Hotez P. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471-84. doi: 10.1161/CIRCULATIONAHA.121.056135.
20. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac auto-antibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4:411–7. doi: 10.1016/ s1388-9842(02)00010-7.
21. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi: 10.1056/NEJMoa2034577.
22. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. doi: 10.1056/NEJMoa2035389.
23. Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could Sars-Coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524. doi: 10.1016/j.autrev.2020.102524.
24. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi: 10.1016/j. clim.2020.108480.
25. Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38:7–46. doi: 10.1016/j.cpcardiol.2012.07.003.
26. Girón-González JA, Moral FJ, Elvira J, García-Gil D, Guerrero F, Gavilán I, Escobar L. Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol. 2000;143:31–6. doi: 10.1530/eje.0.1430031.
27. Frisancho-Kiss S, Coronado MJ, Frisancho JA, Lau VM, Rose NR, Klein SL, et al. Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun. 2009;23:649–57. doi: 10.1016/j.bbi.2008.12.002.
28. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130:1601–6. doi: 10.1161/CIRCULATIONAHA.114.010376.
29. Das B, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?. Children. 2021;8:607. doi: https://doi.org/10.3390/children 8070607.
30. Ammirati E, Cavallotti C, Milazzo A, Pedrotti P, Soriano F. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc. 2021;34.100774. doi: https://doi.org/10.1016/j.ijcha.2021.100774.
31. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019 (COVID-19) vaccines. July 6, 2021. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html.
32. Ministry of Health Singapore. Expert committee on covid-19 vaccination statement on skin reactions after vaccination and refraining from strenuous physical activity after vaccination; Ministry of Health Singapore: 16th Sep 2021. https://wPCRww.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination-statement-on-skin-reactions-after-vaccination-and-refraining-from-strenuous-physical-activity-after-vaccination.
33. Patone, M., Mei, X.W., Handunnetthi, L. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med (2021). https://doi.org/10.1038/s41591-021-01630-0
34. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021; 385: 1078-90. DOI: 10.1056/NEJMoa2110475

Masuk atau Daftar

Nomor Ponsel Sudah Terdaftar

Masuk dengan Email

Masuk dengan Email

Masuk dengan Facebook

Masuk atau Daftar

Referensi

Artikel Terkait